BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Glaxo  Group  Ltd  submitted  on  15  March  2007  an  application  for  Marketing 
Authorisation to the European Medicines Agency (EMEA) for Orlistat GSK, through the centralised 
procedure of Regulation (EC) No 726/2004.  
The  legal  basis  for  this  application  refers  to  Article  10(c)  of  Directive  2001/83/EC,  as  amended, 
relating to informed consent from the marketing authorisation holder, Roche Registration Limited, for 
the authorised medicinal product XENICAL (EU/1/98/071/001-006). 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The  initial  product,  XENICAL,  has  been  given  a  Community  Marketing  Authorisation  on  29  July 
1998. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Co-Rapporteur: George Aislaitner 
Rapporteur: Julia Dunne 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 15 March 2007. 
The procedure started on 25 March 2007.  
The Rapporteur's first Assessment Report was circulated to all CHMP members on 1 May 2007. 
The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 30 April 
2007.  
The  Rapporteurs  circulated  the  Joint  Assessment  Report  to  all  CHMP  members  on  21  May 
2007. 
During the meeting on 21-24 May 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to Orlistat GSK on 24 May 2007. The applicant provided the letter of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 17 May 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 23 July 2007. 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
